| Item Type | Name |
|
Concept
|
Prognosis
|
|
Academic Article
|
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic.
|
|
Academic Article
|
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
|
|
Academic Article
|
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
|
|
Academic Article
|
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
|
|
Academic Article
|
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
|
|
Academic Article
|
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer.
|
|
Academic Article
|
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
|
|
Academic Article
|
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
|
|
Academic Article
|
Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
|
|
Academic Article
|
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
|
|
Academic Article
|
SMO mutations confer poor prognosis in malignant pleural mesothelioma.
|
|
Academic Article
|
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
|
|
Academic Article
|
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
|
|
Academic Article
|
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
|
|
Academic Article
|
Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
|
|
Academic Article
|
Predictive models in palliative care.
|
|
Academic Article
|
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
|
|
Academic Article
|
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
|
|
Academic Article
|
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
|
|
Academic Article
|
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.
|
|
Academic Article
|
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab.
|
|
Academic Article
|
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
|
|
Academic Article
|
Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.
|
|
Academic Article
|
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
|
|
Academic Article
|
Treatment of lung large cell neuroendocrine carcinoma.
|
|
Academic Article
|
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
|
|
Academic Article
|
Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
|
|
Academic Article
|
Thymoma and thymic carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations.
|
|
Academic Article
|
LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
|
|
Academic Article
|
Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
|
|
Academic Article
|
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.
|
|
Academic Article
|
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
|
|
Academic Article
|
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
|
|
Academic Article
|
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
|